Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gimatecan in Platinum-Resistant Recurrent Ovarian Cancer
NCT04846842Phase 2Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gimatecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Lee's Pharmaceutical Holdings Limited. Status: unknown.
02
Drugs
gimatecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04846842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846842.